The number of U.S. employers who cover obesity medications, including Wegovy from Novo Nordisk that belongs to a class of GLP-1 drugs, could nearly double next year, according to a survey.
Tag: Ozempic
Insurers Paying Close Attention to Obesity Drugs as Demand Rises
There isn’t much stopping a new class of obesity-diabetes drugs from becoming one of the pharmaceutical industry’s biggest blockbusters.